Precision Medicine

At SXSW, Reckitt Catalyst and Serena Williams unveil a new cohort of U.S. entrepreneurs tackling America's deep-rooted healthcare access crisis.

A legislative movement across 11 states aims to make scalp cooling, a therapy to prevent hair loss during chemo, an insured part of cancer treatment.

A landmark review decodes how ketogenic diets treat epilepsy, highlighting a major research gap and sparking a quest for drugs that mimic the diet's effects.

One year post-approval, Neurotech's novel gene therapy implant is transforming patient lives and rewriting the playbook for biotech commercialization.

A global campaign is rebranding the canned sardine as a weapon against metabolic disease. We investigate the science, the strategy, and a $12 wellness plan.

A groundbreaking clinical trial shows a nutrition-based therapy extended life by 34% in stage IV pancreatic cancer patients, offering rare hope.

New research shows a telehealth model boosting GLP-1 results to over 26% weight loss, but its reliance on unapproved compounded drugs raises safety flags.

The specialty infusion provider is the first to earn a rigorous new distinction, signaling a major leap forward in patient safety and quality of care.

A plant-based gel that stops severe bleeding in seconds is being showcased to top trauma experts, signaling a major shift in emergency medicine.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

After a massive divestiture and balance sheet overhaul, Elutia is all-in on its next-gen biomatrix, NXT-41x, to disrupt the $1.5B breast surgery market.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

Microsoft partners with Neuro-AI pioneer HABS to create AI that understands human cognition, ushering in an era of unprecedented innovation and ethical debate.

Petcurean launches a groundbreaking pet food combining dental and immune support, backed by clinical trials and poised to disrupt the premium market.

Eight innovators receive a major prize to pursue high-risk, radical ideas in the fight against Alzheimer’s, aiming to change the paradigm of neuroscience.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

PainTEQ's landmark deal, crowned 'Deal of the Year,' showcases a new model for medtech growth and its patient-first mission in pain management.